

Galectin announces new CEO

13 June 2018 | News

Prior to his work at Galectin, Dr. Shlevin served Georgia Institute of Technology's Advanced Technology Development Center as manager of bioscience partnering and commercialization efforts.



Singapore- Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins, announced that Harold H. Shlevin, Ph.D., currently the Company's Chief Operating Officer (COO), has been appointed Chief Executive Officer (CEO) and President to succeed Peter G. Traber, M.D., who has resigned as President, CEO and Chief Medical Officer. The transition will be effective July 6, 2018.

Prior to his work at Galectin, Dr. Shlevin served Georgia Institute of Technology's Advanced Technology Development Center as manager of bioscience partnering and commercialization efforts.

Board Chairman Richard Uihlein commented, "As the Company enters this next strategic phase, we are extremely pleased that Dr. Harold Shlevin, who has been Galectin's COO since 2012, and who has extensive healthcare leadership experience, has agreed to take on the broader role of CEO at this critical juncture. Harold has significant business development experience as an executive and will be responsible for directing and overseeing the potential partnering of our NASH Phase 3 compound. Dr. Shlevin will also oversee future NASH cirrhosis trials and is responsible for the Company's clinical trials in cancer immunotherapy and any other potential new clinical trials in other indications.